The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Johnson & Johnson Vision announced today that it launched an expanded range of Acuvue Abiliti overnight lenses, as well as a new intraocular lens.

The FDA approved an expanded range of the Acuvue Abiliti overnight therapeutic lenses for myopia (nearsightedness) management. The approval covers lenses up to six diopters, widening the range from the previously approved four diopters. (J&J announced the initial FDA approval in May 2021.)

Johnson & Johnson Vision officials think Acuvue Abiliti could help slow the progression of myopia among children, protecting them from potentially serious eye conditions that can arise from severe nearsightedness late in life.

Abiliti overnight lenses, orthokeratology (ortho-k) lenses, temporarily reduce refractive error. Subject to a professional myopia management plan, the lenses may eliminate the need to wear contacts or glasses during waking hours after removal. According to a news release, Johnson & Johnson Vision designed them to match a patient’s eye based on corneal shape and prescription.

J&J Vision featured in MassDevice’s 5 top ophthalmic device innovations you need to know. READ HERE

The offering features FitAbility software to guide professionals through the fitting process. It recommends a lens with a first-fit success rate of approximately 90%.

Each annual purchase of Abiliti provides a free eye health exam to a child in need through the Sight for Kids program. Johnson & Johnson Vision now offers the Abiliti overnight lenses nationwide in two designs. They cover myopia management and myopia management for astigmatism.

“By expanding the parameters for Abiliti overnight lenses, it creates more opportunities for eye care professionals to reach even more patients,” said Dr. Chandra Mickles , North America professional education lead, myopia, Johnson & Johnson Vision. “The expansion of treatment options comes at a critical time as myopia rates continue to rise among children. At Johnson & Johnson Vision, we remain committed to changing the trajectory of myopia with evidence-based strategies and professional support.”

Johnson & Johnson Vision also launched its presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology.

The lens expands presbyopia correction to more patients. It also joins the TECNIS Synergy IOL, a hybrid lens for spectacle independence, in the InteliLight portfolio.

Johnson & Johnson Vision combines its violet-light filter, echelette design and achromatic technology in the TECNIS Symfony OptiBlue IOL. It blocks the shortest wavelengths of light that produce the most light scatter. The echelette design helps to reduce light scattering and halo intensity. Additionally, the achromatic technology corrects chromatic aberration for better contrast day and night.

“We know our patients’ lives don’t stop at sunset, and neither should their confidence in being able to see clearly or drive at night,” said Nikki Sidi , VP, global strategic marketing, surgical vision, Johnson & Johnson Vision. “The InteliLight PCIOL portfolio delivers best-in-category contrast and low-light performance. And with TECNIS Synergy for spectacle independence and TECNIS Symfony OptiBlue for functional vision at every distance, surgeons can now choose the best in low-light performing PCIOLs, according to their patients’ needs.”

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), News Well, Optical/Ophthalmic, Regulatory/Compliance Tagged With: FDA, Johnson & Johnson, Johnson & Johnson Vision

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.